Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who wrote (82)	12/8/2000 5:00:39 AM
From: nigel bates	Read Replies (1) of 469

I did hear that there was a £20m overallotment, but this was all that was on the website so far - Oxford GlycoSciences Plc ('OGS' or the 'Company') (LSE: OGS; NASDAQ: OGSI) announces that the upper target of £150 million ($216 million) from its Open Offer and International Offering has been met before deduction of expenses. The Price for both Offers has been set at 1275p ($18.36) per new Ordinary Share. On this basis, the number of new Ordinary Shares to be issued under the Open Offer is 2.77 million. The number of new Ordinary Shares being offered through the International Offering is 9.00 million. The Company has granted to the Managers an option to subscribe for up to 1.6 million additional new Ordinary Shares at the Offer Price to cover over-allotments. Excluding the Over-Allotment Option, the net proceeds to the Company (after managers' commissions and other expenses of the Offers) will be approximately £137.5 million ($198 million). Lehman Brothers was lead manager, sole book runner and global coordinator for this offering. The co-managers were Credit Suisse First Boston and Cazenove.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next